Home Proteases HCV Protease inhibitor Pibrentasvir (ABT-530) For research use only.

Pibrentasvir (ABT-530)

Pibrentasvir (ABT-530) is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50 ranging from 1.4 pM to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.

Pibrentasvir (ABT-530) Chemical Structure

Pibrentasvir (ABT-530) Chemical Structure

CAS No. 1353900-92-1

Purity & Quality Control

Batch: S964101 DMSO]100 mg/mL]false]Ethanol]100 mg/mL]false]Water]Insoluble]false Purity: 98.35%
98.35

Pibrentasvir (ABT-530) Related Products

Signaling Pathway

HCV Protease Signaling Pathways

HCV Protease Signaling Pathway

Biological Activity

Description Pibrentasvir (ABT-530) is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50 ranging from 1.4 pM to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.
Targets
GT5a [1]
(Cell-free assay)		 GT1a H77 [1]
(Cell-free assay)		 GT2b [1]
(Cell-free assay)		 GT4a [1]
(Cell-free assay)		 GT3a [1]
(Cell-free assay)		 Click to View More Targets
1.4 pM(EC50) 1.8 pM(EC50) 1.9 pM(EC50) 1.9 pM(EC50) 2.1 pM(EC50)
In vitro
In vitro

Pibrentasvir is a next-generation HCV NS5A inhibitor with potent and pan-genotypic activity, and it maintains activity against common amino acid substitutions of HCV genotypes 1 to 6 that are known to confer resistance to currently approved NS5A inhibitors.[1]
Cell Research Cell lines Huh-7 human hepatoma cell line, CEM-SS cells
Concentrations --
Incubation Time 6 days
Method

Antiviral activity assays for HIV-1 and HBV are performed at Southern Research Institute. Pibrentasvir is tested in an HIV-1 antiviral cytoprotection assay using CEM-SS cells and the IIIB strain of HIV-1. Briefly, virus and cells are mixed in the presence of pibrentasvir or zidovudine (AZT; positive control) and incubated for 6 days. The titers of the virus are determined beforehand such that the virus-infected control wells exhibited approximately 85% to 95% loss of cell viability due to virus replication. Therefore, antiviral effect or cytoprotection is observed when a compound prevented virus replication. Six days after infection, 20 to 25 μl of MTS reagent is added per well, and the microtiter plates are then incubated for 4 to 6 h to assess cell viability. Plates are read spectrophotometrically at 490/650 nm with a Molecular Devices Vmax or SpectraMax Plus plate reader.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04577482 Completed
Hepatitis C Virus (HCV)
AbbVie
 October 7 2020 --
NCT03303599 Completed
Hepatitis C
AbbVie
 November 13 2017 --
NCT02441283 Completed
Hepatitis C
AbbVie
 June 22 2015 Phase 2|Phase 3
NCT02442258 Completed
Renal Impairment
AbbVie
 March 2015 Phase 1
NCT02296905 Completed
Hepatic Impairment
AbbVie
 October 2014 Phase 1

Chemical Information & Solubility

Molecular Weight 1113.18 Formula

C57H65F5N10O8
CAS No. 1353900-92-1 SDF --
Smiles CC(C(C(=O)N1CCCC1C2=NC3=C(N2)C=C(C(=C3)F)C4CCC(N4C5=CC(=C(C(=C5)F)N6CCC(CC6)C7=CC=C(C=C7)F)F)C8=CC9=C(C=C8F)N=C(N9)C1CCCN1C(=O)C(C(C)OC)NC(=O)OC)NC(=O)OC)OC
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 100 mg/mL ( (89.83 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 100 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Pibrentasvir (ABT-530) | Pibrentasvir (ABT-530) supplier | purchase Pibrentasvir (ABT-530) | Pibrentasvir (ABT-530) cost | Pibrentasvir (ABT-530) manufacturer | order Pibrentasvir (ABT-530) | Pibrentasvir (ABT-530) distributor